Alpha 2.0
Login Register
» Articles » PMID: 18239622

Preclinical Targeting of NF-kappaB and FLT3 Pathways in AML Cells

Overview
Journal Leukemia
Specialties Hematology
Oncology
Date 2008 Feb 2
PMID 18239622
Citations 10
Authors
E Griessinger
C Frelin
N Cuburu
V Imbert
C Dageville
M Hummelsberger
N Sirvent
M Dreano
J-F Peyron
Affiliations
Soon will be listed here.
Citing Articles

miR-29b-3p suppresses the malignant biological behaviors of AML cells via inhibiting NF-κB and JAK/STAT signaling pathways by targeting HuR.

Tang Y, Wu W, Chen Q, Liu S, Zheng Z, Cui Z BMC Cancer. 2022; 22(1):909.

PMID: 35986311 PMC: 9392259. DOI: 10.1186/s12885-022-09996-1.

Lower RNA expression of ALDH1A1 distinguishes the favorable risk group in acute myeloid leukemia.

Dancik G, Voutsas I, Vlahopoulos S Mol Biol Rep. 2022; 49(4):3321-3331.

PMID: 35028852 DOI: 10.1007/s11033-021-07073-7.

Overcoming adaptive therapy resistance in AML by targeting immune response pathways.

Melgar K, Walker M, Jones L, Bolanos L, Hueneman K, Wunderlich M Sci Transl Med. 2019; 11(508).

PMID: 31484791 PMC: 6985905. DOI: 10.1126/scitranslmed.aaw8828.

Antitumor Mechanism of the Essential Oils from Two Succulent Plants in Multidrug Resistance Leukemia Cell.

Poma P, Labbozzetta M, McCubrey J, Ramarosandratana A, Sajeva M, Zito P Pharmaceuticals (Basel). 2019; 12(3).

PMID: 31454963 PMC: 6789815. DOI: 10.3390/ph12030124.

Novel Targeted Nano-Parthenolide Molecule against NF-kB in Acute Myeloid Leukemia.

Darwish N, Sudha T, Godugu K, Bharali D, Elbaz O, El-Ghaffar H Molecules. 2019; 24(11).

PMID: 31163672 PMC: 6600366. DOI: 10.3390/molecules24112103.